
Solventum Corporation (SOLV)
$
67.14
+0.04 (0.06%)
Key metrics
Financial statements
Free cash flow per share
-0.0574
Market cap
11.6 Billion
Price to sales ratio
1.3984
Debt to equity
0.9972
Current ratio
1.2305
Income quality
0.2371
Average inventory
1.1 Billion
ROE
0.3674
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Solventum Corporation, a healthcare company incorporated in 2023 and based in Saint Paul, Minnesota, is focused on developing, manufacturing, and commercializing a diverse range of solutions to meet critical customer and patient needs. The company operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment offers an array of products, including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. Meanwhile, the Dental Solutions segment provides an extensive suite of dental and orthodontic products such as brackets, aligners, restorative cements, and bonding agents. Health Information Systems is dedicated to delivering software solutions like computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. In addition, the Purification and Filtration segment features advanced purification and filtration technologies encompassing filters, purifiers, cartridges, and membranes. The company's operating expenses amount to $2,270,000,000.00 encompassing various operational costs incurred. With reported revenue of $8,325,000,000.00 the company reflects a strong market presence. Moreover, the operating income ratio stands at 0.26 indicating the company's operational profitability margin, while the weighted average number of shares outstanding is 174,100,000.00 highlighting the company's shareholder base. The company's stock is identified with the symbol 'SOLV' in the market. Investors will find the stock reasonably priced at $73.72 appealing to a broad range of market participants. With an average trading volume of 1,088,171.00 the stock indicates moderate liquidity, which can facilitate trading activities for shareholders. Solventum Corporation boasts a mid-range market capitalization of $11,648,320,356.00 establishing it as a steady performer. As a key player in the Medical - Care Facilities industry, the company significantly contributes to the overall market landscape, driving innovation and growth within the healthcare sector, wherein it belongs to the Healthcare sector. This combination of solid financial performance and strategic positioning underscores Solventum Corporation’s potential as a valuable investment opportunity within the dynamic healthcare market.
Investing in Solventum Corporation (SOLV) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A-, with a Bearish outlook. Always conduct your own research before investing.
Analysts predict Solventum Corporation stock to fluctuate between $60.70 (low) and $88.20 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2026-03-20, Solventum Corporation's market cap is $11,648,320,356, based on 173,493,005 outstanding shares.
Compared to Meta Platforms, Inc. Class A Common Stock, Solventum Corporation has a Lower Market-Cap, indicating a difference in performance.
To buy Solventum Corporation (SOLV) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SOLV. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Revenue: $8,325,000,000 | EPS: $8.94 | Growth: 222.74%.
Visit https://www.solventum.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $88.20 (2025-12-02) | All-time low: $47.16 (2024-07-16).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News

seekingalpha.com
Solventum Corporation (SOLV) Presents at 2026 KeyBanc Capital Markets Healthcare Forum Transcript

zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

seekingalpha.com
Solventum shares have traded sideways post-spin, as investors digest separation impacts, stranded costs, and recent capital allocation moves. Despite a $4.1B divestment and targeted $500M cost savings, 2025 results showed minimal free cash flow and only modest earnings growth. 2026 guidance calls for 2-3% organic sales growth and adjusted EPS of $6.50, but free cash flow remains weak at ~$200M.

zacks.com
SOLV's Q4 earnings and revenues beat estimates, driven by organic growth across MedSurg, Dental and HIS, despite margins declined.

seekingalpha.com
Solventum Corporation (SOLV) Q4 2025 Earnings Call Transcript

zacks.com
The headline numbers for Solventum (SOLV) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

zacks.com
Solventum (SOLV) came out with quarterly earnings of $1.57 per share, beating the Zacks Consensus Estimate of $1.5 per share. This compares to earnings of $1.41 per share a year ago.

reuters.com
Medical device maker Solventum on Thursday beat Wall Street estimates for the fourth quarter, helped by strong demand for its wound care and sterilization products.

zacks.com
SOLV readies Q4 results amid solid momentum, tariff headwinds, and M&A focus as investors watch margins and growth trends closely.

reuters.com
SOLV Energy's shares rose 20% in its New York debut on Wednesday, giving the solar and battery storage firm a valuation of $5.98 billion, underscoring a strong rebound in IPO activity in 2026.
See all news